Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic… Expand
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
In subjects with mild/moderate renal impairment, both febuxostat doses were more efficacious than allopurinol and equally safe and at the doses tested, safety of febUXostat and allopURinol was comparable. Expand
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.
- T. Niewold, J. Kelly, Marie H Flesch, L. Espinoza, J. Harley, M. Crow
- Biology, Medicine
- Arthritis and rheumatism
- 1 August 2008
The IRF5 SLE risk haplotype is associated with higher serum IFNalpha activity in SLE patients, and this effect is most prominent in patients positive for either anti-RBP or anti-dsDNA autoantibodies. Expand
HLA-B27-Associated Reactive Arthritis: Pathogenetic and Clinical Considerations
SUMMARY Current evidence supports the concept that reactive arthritis (ReA) is an immune-mediated synovitis resulting from slow bacterial infections and showing intra-articular persistence of viable,… Expand
Experience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects
MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease, and its targeted antifibrotic properties make it a potentially more effective agent than CYC that may supplant it as a first-line agent or provide sensible post-CYC maintenance or synergistic strategy in the treatment of CTD-ILD. Expand
Pulmonary involvement in rheumatoid arthritis.
- J. Anaya, L. Diethelm, +4 authors L. Espinoza
- Seminars in arthritis and rheumatism
- 1 February 1995
Pulmonary involvement is one of the extra-articular manifestations of rheumatoid arthritis and includes pleurisy, parenchymal nodules, interstitial involvement, and airway disease and may occur concurrently with pulmonary nodulosis or interstitial disease. Expand
Prolactin and autoimmunity.
Evidence support the important role of PRL in autoimmunity and autoimmune diseases, mainly SLE, where HPRL stimulated the production of autoantibodies. Expand
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
- P. Helliwell, O. FitzGerald, +34 authors J. Walsh
- Annals of the rheumatic diseases
- 13 July 2012
Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller. Expand
Psoriatic arthritis: clinical response and side effects to methotrexate therapy.
- L. Espinoza, L. Zakraoui, +5 authors P. Martínez-Osuna
- The Journal of rheumatology
- 1 June 1992
It is concluded that methotrexate is an effective and safe agent in PsA and results indicate that it is not necessary to perform liver biopsies on a routine basis. Expand
Reactive arthritis: newer developments.
- D. Flores, J. Márquez, M. Garza, L. Espinoza
- Rheumatic diseases clinics of North America
- 1 February 2003
Conventional antirheumatic therapeutic modalities based on nonsteroid anti-inflammatory drugs, sulfasalazine, and steroids are effective in the majority of patients, although the use of second-line agents including methotrexate and more recently biological agents such as etanercept and infliximab has been found highly effective. Expand